Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer

INTRODUCTION: Prostate cancer with a microsatellite instability‐high or mismatch repair‐deficient status is not common. Few reports of the response to pembrolizumab in metastatic castration‐resistant prostate cancer in a real‐world setting have been reported. This case report describes a dramatic re...

Descripción completa

Detalles Bibliográficos
Autores principales: Kageyama, Takumi, Soga, Norihito, Sekito, Sho, Kato, Seiichi, Ogura, Yuji, Kojima, Takahiro, Kanai, Masahiro, Inoue, Takahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626308/
https://www.ncbi.nlm.nih.gov/pubmed/36341181
http://dx.doi.org/10.1002/iju5.12508
_version_ 1784822700451037184
author Kageyama, Takumi
Soga, Norihito
Sekito, Sho
Kato, Seiichi
Ogura, Yuji
Kojima, Takahiro
Kanai, Masahiro
Inoue, Takahiro
author_facet Kageyama, Takumi
Soga, Norihito
Sekito, Sho
Kato, Seiichi
Ogura, Yuji
Kojima, Takahiro
Kanai, Masahiro
Inoue, Takahiro
author_sort Kageyama, Takumi
collection PubMed
description INTRODUCTION: Prostate cancer with a microsatellite instability‐high or mismatch repair‐deficient status is not common. Few reports of the response to pembrolizumab in metastatic castration‐resistant prostate cancer in a real‐world setting have been reported. This case report describes a dramatic response to pembrolizumab after initial pseudoprogression in a patient with microsatellite instability‐high metastatic castration‐resistant prostate cancer. CASE PRESENTATION: A 70‐year‐old man was administered pembrolizumab for metastatic castration‐resistant prostate cancer after the genetic evaluation of lymphadenectomy revealed a microsatellite instability‐high status. His general condition dramatically improved after pseudoprogression. His favorable condition has been maintained for 1 year since the final dose. CONCLUSION: We experienced a case of dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer. In patients with metastatic castration‐resistant prostate cancer and the microsatellite instability‐high/mismatch repair‐deficient phenotype, a few months follow‐up is necessary to evaluate the efficacy of pembrolizumab.
format Online
Article
Text
id pubmed-9626308
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-96263082022-11-03 Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer Kageyama, Takumi Soga, Norihito Sekito, Sho Kato, Seiichi Ogura, Yuji Kojima, Takahiro Kanai, Masahiro Inoue, Takahiro IJU Case Rep Case Reports INTRODUCTION: Prostate cancer with a microsatellite instability‐high or mismatch repair‐deficient status is not common. Few reports of the response to pembrolizumab in metastatic castration‐resistant prostate cancer in a real‐world setting have been reported. This case report describes a dramatic response to pembrolizumab after initial pseudoprogression in a patient with microsatellite instability‐high metastatic castration‐resistant prostate cancer. CASE PRESENTATION: A 70‐year‐old man was administered pembrolizumab for metastatic castration‐resistant prostate cancer after the genetic evaluation of lymphadenectomy revealed a microsatellite instability‐high status. His general condition dramatically improved after pseudoprogression. His favorable condition has been maintained for 1 year since the final dose. CONCLUSION: We experienced a case of dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer. In patients with metastatic castration‐resistant prostate cancer and the microsatellite instability‐high/mismatch repair‐deficient phenotype, a few months follow‐up is necessary to evaluate the efficacy of pembrolizumab. John Wiley and Sons Inc. 2022-08-02 /pmc/articles/PMC9626308/ /pubmed/36341181 http://dx.doi.org/10.1002/iju5.12508 Text en © 2022 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Kageyama, Takumi
Soga, Norihito
Sekito, Sho
Kato, Seiichi
Ogura, Yuji
Kojima, Takahiro
Kanai, Masahiro
Inoue, Takahiro
Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer
title Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer
title_full Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer
title_fullStr Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer
title_full_unstemmed Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer
title_short Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer
title_sort dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626308/
https://www.ncbi.nlm.nih.gov/pubmed/36341181
http://dx.doi.org/10.1002/iju5.12508
work_keys_str_mv AT kageyamatakumi dramaticresponsetopembrolizumabafterpseudoprogressioninapatientwithadvancedmetastaticcastrationresistantprostatecancer
AT soganorihito dramaticresponsetopembrolizumabafterpseudoprogressioninapatientwithadvancedmetastaticcastrationresistantprostatecancer
AT sekitosho dramaticresponsetopembrolizumabafterpseudoprogressioninapatientwithadvancedmetastaticcastrationresistantprostatecancer
AT katoseiichi dramaticresponsetopembrolizumabafterpseudoprogressioninapatientwithadvancedmetastaticcastrationresistantprostatecancer
AT ogurayuji dramaticresponsetopembrolizumabafterpseudoprogressioninapatientwithadvancedmetastaticcastrationresistantprostatecancer
AT kojimatakahiro dramaticresponsetopembrolizumabafterpseudoprogressioninapatientwithadvancedmetastaticcastrationresistantprostatecancer
AT kanaimasahiro dramaticresponsetopembrolizumabafterpseudoprogressioninapatientwithadvancedmetastaticcastrationresistantprostatecancer
AT inouetakahiro dramaticresponsetopembrolizumabafterpseudoprogressioninapatientwithadvancedmetastaticcastrationresistantprostatecancer

Ejemplares similares